Clinical significance of FBXW7 loss of function in human cancers
- PMID: 35346215
- PMCID: PMC8962602
- DOI: 10.1186/s12943-022-01548-2
Clinical significance of FBXW7 loss of function in human cancers
Abstract
FBXW7 (F-Box and WD Repeat Domain Containing 7) (also referred to as FBW7 or hCDC4) is a component of the Skp1-Cdc53 / Cullin-F-box-protein complex (SCF/β-TrCP). As a member of the F-box protein family, FBXW7 serves a role in phosphorylation-dependent ubiquitination and proteasome degradation of oncoproteins that play critical role(s) in oncogenesis. FBXW7 affects many regulatory functions involved in cell survival, cell proliferation, tumor invasion, DNA damage repair, genomic instability and telomere biology. This thorough review of current literature details how FBXW7 expression and functions are regulated through multiple mechanisms and how that ultimately drives tumorigenesis in a wide array of cell types. The clinical significance of FBXW7 is highlighted by the fact that FBXW7 is frequently inactivated in human lung, colon, and hematopoietic cancers. The loss of FBXW7 can serve as an independent prognostic marker and is significantly correlated with the resistance of tumor cells to chemotherapeutic agents and poorer disease outcomes. Recent evidence shows that genetic mutation of FBXW7 differentially affects the degradation of specific cellular targets resulting in a distinct and specific pattern of activation/inactivation of cell signaling pathways. The clinical significance of FBXW7 mutations in the context of tumor development, progression, and resistance to therapies as well as opportunities for targeted therapies is discussed.
Keywords: Aneuploidy; Apoptosis; CDC4; Cancer; Cell cycle; Centrosome; Chromosome instability; Cyclin E; DNA repair; Drug resistance; Epigenetic; FBW7; FBXW7; Immunotherapy; LncRNA; MCL-1; MYC; Mutation; NOTCH; Non-coding RNA; Tumor suppressor; circRNA; miRNA.
© 2022. The Author(s).
Conflict of interest statement
Authors declare no financial conflict of interest. Dr. Nicot is an editorial board member of
Figures
![Fig. 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8962602/bin/12943_2022_1548_Fig1_HTML.gif)
![Fig. 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8962602/bin/12943_2022_1548_Fig2_HTML.gif)
![Fig. 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8962602/bin/12943_2022_1548_Fig3_HTML.gif)
![Fig. 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8962602/bin/12943_2022_1548_Fig4_HTML.gif)
![Fig. 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8962602/bin/12943_2022_1548_Fig5_HTML.gif)
Similar articles
-
The HTLV-I oncoprotein Tax inactivates the tumor suppressor FBXW7.J Virol. 2024 Jul 23;98(7):e0040524. doi: 10.1128/jvi.00405-24. Epub 2024 Jun 14. J Virol. 2024. PMID: 38874362
-
FBXW7: a critical tumor suppressor of human cancers.Mol Cancer. 2018 Aug 7;17(1):115. doi: 10.1186/s12943-018-0857-2. Mol Cancer. 2018. PMID: 30086763 Free PMC article. Review.
-
Recent insight into the role of FBXW7 as a tumor suppressor.Semin Cancer Biol. 2020 Dec;67(Pt 2):1-15. doi: 10.1016/j.semcancer.2020.02.017. Epub 2020 Feb 27. Semin Cancer Biol. 2020. PMID: 32113998 Review.
-
The FBXW7-NOTCH interactome: A ubiquitin proteasomal system-induced crosstalk modulating oncogenic transformation in human tissues.Cancer Rep (Hoboken). 2021 Aug;4(4):e1369. doi: 10.1002/cnr2.1369. Epub 2021 Apr 6. Cancer Rep (Hoboken). 2021. PMID: 33822486 Free PMC article. Review.
-
The Role of FBXW7 in Gynecologic Malignancies.Cells. 2023 May 17;12(10):1415. doi: 10.3390/cells12101415. Cells. 2023. PMID: 37408248 Free PMC article. Review.
Cited by
-
The HTLV-I oncoprotein Tax inactivates the tumor suppressor FBXW7.J Virol. 2024 Jul 23;98(7):e0040524. doi: 10.1128/jvi.00405-24. Epub 2024 Jun 14. J Virol. 2024. PMID: 38874362
-
Protein Arginine Methyltransferases in Pancreatic Ductal Adenocarcinoma: New Molecular Targets for Therapy.Int J Mol Sci. 2024 Apr 2;25(7):3958. doi: 10.3390/ijms25073958. Int J Mol Sci. 2024. PMID: 38612768 Free PMC article. Review.
-
The FBXW7-binding sites on FAM83D are potential targets for cancer therapy.Breast Cancer Res. 2024 Mar 7;26(1):37. doi: 10.1186/s13058-024-01795-9. Breast Cancer Res. 2024. PMID: 38454442 Free PMC article.
-
Sintilimab with two cycles of chemotherapy for the treatment of advanced squamous non-small cell lung cancer: a phase 2 clinical trial.Nat Commun. 2024 Feb 19;15(1):1512. doi: 10.1038/s41467-024-45769-z. Nat Commun. 2024. PMID: 38374204 Free PMC article. Clinical Trial.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials